16. Jahreskongress für Klinische Pharmakologie
Verbund Klinische Pharmakologie in Deutschland
09. - 10. Oktober 2014, Köln
Abstracts
Meeting Abstract
(14vklipha01)
[Full Text]
The impact of German benefit assessment on endpoint selection in clinical research and drug development in Germany – lessons (to be) learned
Patchev A, Rost M, Engler C, Obermeier M, Hautmann C[Full Text]
Meeting Abstract
(14vklipha02)
[Full Text]
Induction of PCFT and OATP1A2 via vitamin D receptor activation in vitro is not confirmed in vivo in healthy volunteers after a 10-days treatment with 1,25-dihydroxyvitamin D3
Marti I, Claro da Silva T, Spanaus K, Gubler C, Kullak-Ublick GA, Jetter A[Full Text]
Meeting Abstract
(14vklipha03)
[Full Text]
Therapeutic drug monitoring (TDM) of the HIV drugs abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, lopinavir, and nevirapine
Donnerer J[Full Text]
Meeting Abstract
(14vklipha04)
[Full Text]
Serelaxin – from basic research to clinical practice in acute heart failure [invited speaker]
Dschietzig TB[Full Text]
Meeting Abstract
(14vklipha05)
[Full Text]
Detection of medication errors requires more than just medication data
Plank-Kiegele B, Bürkle T, Müller F, Patapovas A, Sonst A, Pfistermeister B, Dormann H, Maas R[Full Text]
Meeting Abstract
(14vklipha06)
[Full Text]
Dose individualisation of antiinfective drugs in clinical practice [invited speaker]
Frey OR, Röhr A, Helbig S, Köberer A[Full Text]
Meeting Abstract
(14vklipha07)
[Full Text]
SATB1 as a putative therapeutic target in colorectal cancer
Frömberg A, Rabe M, Linnebacher M, Aigner A[Full Text]
Meeting Abstract
(14vklipha08)
[Full Text]
Anabolic and other potentially performance enhancing agents in sports [invited speaker]
Thevis M[Full Text]
Meeting Abstract
(14vklipha09)
[Full Text]
Around two thirds of the sildenafil used may be illegal Consumption of illicit sildenafil might dwarf the consumption of legitimate versions [invited speaker]
Venhuis BJ, de Voogt P, Emke E, Causanilles A, Keizers P[Full Text]
Meeting Abstract
(14vklipha10)
[Full Text]
The effect of eye drops containing hyaluronic acid on tear film thickness in healthy subjects
Schmidl D, Kaya S, Schmetterer L, Witkowska K, Unterhuber A, Aranha Dos Santos V, Baar C, Garhöfer G, Werkmeister R[Full Text]
Meeting Abstract
(14vklipha11)
[Full Text]
Clinical research in the doctor's practice: Possibilities and limitations. Strengths and weaknesses [invited speaker]
Hommer A[Full Text]
Meeting Abstract
(14vklipha12)
[Full Text]
Finerenone (BAY 94-882): New Hope for Patients Suffering from Cardio/Renal Diseases [invited speaker]
Nowack C, Kolkhof P[Full Text]
Meeting Abstract
(14vklipha13)
[Full Text]
Size matters? Clinical development outside large research sites – the industry perspective [invited speaker]
Baumgartner C[Full Text]
Meeting Abstract
(14vklipha14)
[Full Text]
Comparison of pantoprazole concentrations in simultaneous cerebrospinal fluid and serum samples
Sigaroudi A, Stelzer C, Braun T, Schröter M, Kinzig M, Fuhr U, Holzgrabe U, Sörgel F[Full Text]
Meeting Abstract
(14vklipha15)
[Full Text]
Specific challenges of topical drug therapy in ophthalmology [invited speaker]
Garhöfer G[Full Text]
Meeting Abstract
(14vklipha16)
[Full Text]
Endurance sports and analgesics: a prospective cohort study on adverse event incidence and dose dependency
Renner B, Küster M, Oppel P, Niederweis U, Brune K[Full Text]
Meeting Abstract
(14vklipha17)
[Full Text]
Old drugs: are they really safe and worth the (low) price? [invited speaker]
Brune K[Full Text]
Meeting Abstract
(14vklipha18)
[Full Text]
Benefit assessment of older drugs [invited speaker]
Biester K[Full Text]
Meeting Abstract
(14vklipha19)
[Full Text]
10 years as an inspector in small clinical research units: developments, retrospection, and perspective [invited speaker]
Hönel A[Full Text]
Meeting Abstract
(14vklipha20)
[Full Text]
Plasma and soft tissue pharmacokinetics of ceftaroline after single and repeated administration of two dosing regimens of ceftaroline fosamil – a microdialysis study in healthy volunteers
Matzneller P, Lackner E, Severin P, Zeitlinger M[Full Text]
Meeting Abstract
(14vklipha21)
[Full Text]
Quantitative significance of intestinal drug transporters for drug therapy [invited speaker]
Siegmund W[Full Text]
Meeting Abstract
(14vklipha22)
[Full Text]
A survey among leading pharmaceutical companies on the impact of clinical trial registries for patient participation and recruitment
Yildirim O, Herdegen T, Michel MC[Full Text]
Meeting Abstract
(14vklipha23)
[Full Text]
Silexan, an orally administered lavender oil preparation for anxiety disorders [invited speaker]
Dienel A[Full Text]
Meeting Abstract
(14vklipha24)
[Full Text]
Novel Approaches for Dose Individualization in Anti-Cancer Drug Therapy [invited speaker]
Jaehde U[Full Text]
Meeting Abstract
(14vklipha25)
[Full Text]
Assessment of the Inhibitory Potential of Spasmolytics on Major Human Cytochrome P450 Enzymes
Dahlinger D, Frechen S, Nücken D, Fuhr U[Full Text]
Meeting Abstract
(14vklipha26)
[Full Text]
A Pharmacometric Model Characterizing the Time Course of the Adverse Events in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib
Suleiman AA, Frechen S, Scheffler M, Nogova L, Wolf J, Fuhr U[Full Text]
Meeting Abstract
(14vklipha27)
[Full Text]
Up-to-date treatment options with tyrosine kinase inhibitors in advanced melanoma [invited speaker]
Eigentler T[Full Text]
Meeting Abstract
(14vklipha29)
[Full Text]
Impact of frequently used pharmaceutical excipients on the function of human peptide and cation transporters
Otter M, Oswald S, Keiser M, Siegmund W[Full Text]
Meeting Abstract
(14vklipha30)
[Full Text]
Absolute protein quantification of clinically relevant metabolizing enzymes by mass spectrometry-based targeted proteomics
Busch D, Gröer C, Drozdzik M, Siegmund W, Oswald S[Full Text]
Meeting Abstract
(14vklipha31)
[Full Text]
Safety requirements and timing of safety studies throughout the clinical program for topical products [invited speaker]
Hughes-Formella B[Full Text]
Meeting Abstract
(14vklipha32)
[Full Text]
Targeting metastatic colorectal cancer with the multikinase inhibitor regorafenib [invited speaker]
Strumberg D[Full Text]
Meeting Abstract
(14vklipha33)
[Full Text]
Population pharmacokinetic model for cisplatin during intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC)
Fritsch A, Kullmann M, Zivanovic O, Abramian A, Hilger R, Kuhn W, Jaehde U[Full Text]
Meeting Abstract
(14vklipha34)
[Full Text]
Treatment options for functional gastrointestinal diseases: Motility modulation beyond MCP and domperidone
Madisch A, Vinson BR, Kelber O, Nieber K, Storr M[Full Text]
Meeting Abstract
(14vklipha35)
[Full Text]
Regulatory assessment of cardiovascular safety of medicinal products [invited speaker]
Mittmann C[Full Text]
Meeting Abstract
(14vklipha36)
[Full Text]
Assessment of mucosal integrity of the upper gastrointestinal tract in healthy volunteers prior to treatment with drugs suspected to cause GI lesions
Scheidl E, Benz C, Loeff P, Groneck V, König A, Schulte-Fischedick A, Lück H, Fuhr U[Full Text]
Meeting Abstract
(14vklipha37)
[Full Text]
Benefits and limitations of dosing recommendations from guidelines – How modelling can support evidence-based dose individualisation [invited speaker]
Schäftlein A[Full Text]
Meeting Abstract
(14vklipha38)
[Full Text]
Klinische Studien an Nichteinwilligungsfähigen aus medizinrechtlicher Sicht [invited speaker]
Fischer G[Full Text]
Meeting Abstract
(14vklipha39)
[Full Text]
Clinical studies on herbal medicines in children: A systematic literature analysis
Marquardt P, Kelber O, Kraft K, Nieber K[Full Text]
Meeting Abstract
(14vklipha40)
[Full Text]
Herbal medicinal products in clinical guidelines: Horse chestnut seed extract as “well established use” medicinal product in chronic venous diseases
Müller J, Kelber O, Kraft K[Full Text]
Meeting Abstract
(14vklipha41)
[Full Text]
Valerian: No Clinically Relevant Interactions
Kelber O, Kraft K, Nieber K[Full Text]
Meeting Abstract
(14vklipha42)
[Full Text]
Clinical Trials – EU Regulation; 536/2014. View of the National Competent Authority (NCA) [invited speaker]
Stahl E[Full Text]
Meeting Abstract
(14vklipha43)
[Full Text]
Anthracycline-induced cardiotoxicity: Molecular mechanisms and possible preventive strategies [invited speaker]
Henninger C, Fritz G[Full Text]
Meeting Abstract
(14vklipha44)
[Full Text]
Galenic requirement for topical preparations from the clinical point of view [invited speaker]
Jünger M[Full Text]
Meeting Abstract
(14vklipha45)
[Full Text]
New EU Regulation on “Clinical trials” – an industry perspective
Ruppert T[Full Text]
